Fresh analysis indicates that people who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight at a significantly accelerated pace than those who end traditional diet and exercise plans.
Published data in a prominent medical journal points out that while overweight people can lose substantial amounts of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"People purchasing these medications must be aware of the risk of fast rebound weight gain when the therapy ends," stated lead investigator Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment weight within about 18 months.
Weighing Therapies
The research, which examined dozens of studies involving thousands of patients, contrasted the results of these new drugs with conventional dieting.
Scientists emphasize that people who shed pounds through dieting generally see a less rapid creep back—around 100 grams monthly—once they finish.
Understanding the Rapid Regain
Nutrition scientists believe the mechanism of the drugs is key to understanding the amplified weight return.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels far above than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication leads to appetite is unsuppressed, making excessive eating much more probable."
A Lifelong Condition?
Medical guidelines advise the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Professionals say that, given the high risk of relapse, the treatment is often long-term.
This perspective is echoed by drug manufacturers, who note that the results "highlight the persistent character of excess weight," similar to managing diseases like high blood pressure.
User Experiences
People who have discontinued the jabs explain a powerful return of hunger.
"It felt as if a switch that goes on and I was suddenly extremely hungry," described an individual.
The struggle is compounded if users have not established sustainable lifestyle or habit modifications during therapy.
Widespread Interest
Recent estimates show that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is greater among females than males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians stress that while the jabs are powerful agents for weight loss, they are not a magic solution and long-term success relies on integrated behavioural support.
